Immunologic Characteristics of HIV-infected Individuals Who Make Broadly Neutralizing Antibodies

Overview

Journal Immunol Rev

Specialties Allergy & Immunology
General Surgery

Date 2017 Jan 31

PMID 28133804

Citations 31

Authors

Persephone Borrow

M Anthony Moody

Affiliations

Soon will be listed here.

Abstract

Induction of broadly neutralizing antibodies (bnAbs) capable of inhibiting infection with diverse variants of human immunodeficiency virus type 1 (HIV-1) is a key, as-yet-unachieved goal of prophylactic HIV-1 vaccine strategies. However, some HIV-infected individuals develop bnAbs after approximately 2-4 years of infection, enabling analysis of features of these antibodies and the immunological environment that enables their induction. Distinct subsets of CD4 T cells play opposing roles in the regulation of humoral responses: T follicular helper (Tfh) cells support germinal center formation and provide help for affinity maturation and the development of memory B cells and plasma cells, while regulatory CD4 (Treg) cells including T follicular regulatory (Tfr) cells inhibit the germinal center reaction to limit autoantibody production. BnAbs exhibit high somatic mutation frequencies, long third heavy-chain complementarity determining regions, and/or autoreactivity, suggesting that bnAb generation is likely to be highly dependent on the activity of CD4 Tfh cells, and may be constrained by host tolerance controls. This review discusses what is known about the immunological environment during HIV-1 infection, in particular alterations in CD4 Tfh, Treg, and Tfr populations and autoantibody generation, and how this is related to bnAb development, and considers the implications for HIV-1 vaccine design.

Citing Articles

Antiretroviral Therapy with Ritonavir-Boosted Atazanavir- and Lopinavir-Containing Regimens Correlates with Diminished HIV-1 Neutralization.

Yuste E, Gil H, Garcia F, Sanchez-Merino V Vaccines (Basel). 2024; 12(10).

PMID: 39460342 PMC: 11511486. DOI: 10.3390/vaccines12101176.

The Association of HIV-1 Neutralization in Aviremic Children and Adults with Time to ART Initiation and CD4+/CD8+ Ratios.

Sanchez-Merino V, Martin-Serrano M, Beltran M, Lazaro-Martin B, Cervantes E, Oltra M Vaccines (Basel). 2024; 12(1).

PMID: 38276667 PMC: 10820134. DOI: 10.3390/vaccines12010008.

To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1.

Griffith S, McCoy L Front Immunol. 2021; 12:708227.

PMID: 34737737 PMC: 8560739. DOI: 10.3389/fimmu.2021.708227.

Distinct Features of Germinal Center Reactions in Macaques Infected by SIV or Vaccinated with a T-Dependent Model Antigen.

Trovato M, Ibrahim H, Isnard S, Le Grand R, Bosquet N, Borhis G Viruses. 2021; 13(2).

PMID: 33572146 PMC: 7916050. DOI: 10.3390/v13020263.

-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures.

Li D, Bradley T, Cain D, Pedroza-Pacheco I, Aggelakopoulou M, Parks R Immunohorizons. 2020; 4(11):713-728.

PMID: 33172842 PMC: 8050958. DOI: 10.4049/immunohorizons.2000088.

References

Poignard P, Sabbe R, Picchio G, Wang M, Gulizia R, Katinger H . Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 1999; 10(4):431-8. DOI: 10.1016/s1074-7613(00)80043-6. View

Baba T, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S . Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2):200-6. DOI: 10.1038/72309. View

Mascola J, Stiegler G, Vancott T, Katinger H, Carpenter C, Hanson C . Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000; 6(2):207-10. DOI: 10.1038/72318. View

Schaerli P, Willimann K, Lang A, Lipp M, Loetscher P, Moser B . CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. 2000; 192(11):1553-62. PMC: 2193097. DOI: 10.1084/jem.192.11.1553. View

Wildin R, Ramsdell F, Peake J, Faravelli F, Casanova J, Buist N . X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001; 27(1):18-20. DOI: 10.1038/83707. View

Kim C, Rott L, Clark-Lewis I, Campbell D, Wu L, Butcher E . Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med. 2001; 193(12):1373-81. PMC: 2193300. DOI: 10.1084/jem.193.12.1373. View

Forthal D, Landucci G, Daar E . Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001; 75(15):6953-61. PMC: 114423. DOI: 10.1128/JVI.75.15.6953-6961.2001. View

Parren P, Marx P, Hessell A, Luckay A, Harouse J, Cheng-Mayer C . Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001; 75(17):8340-7. PMC: 115078. DOI: 10.1128/jvi.75.17.8340-8347.2001. View

Moir S, Malaspina A, Ogwaro K, Donoghue E, Hallahan C, Ehler L . HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A. 2001; 98(18):10362-7. PMC: 56966. DOI: 10.1073/pnas.181347898. View

10.

Meffre E, Milili M, Antunes H, Nussenzweig M, Schiff C . Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest. 2001; 108(6):879-86. PMC: 200933. DOI: 10.1172/JCI13051. View

11.

Oxenius A, Fidler S, Brady M, Dawson S, Ruth K, Easterbrook P . Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection. Eur J Immunol. 2001; 31(12):3782-8. DOI: 10.1002/1521-4141(200112)31:12<3782::aid-immu3782>3.0.co;2-#. View

12.

Palacios R, Santos J, Valdivielso P, Marquez M . Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus. 2002; 11(1):60-3. DOI: 10.1191/0961203302lu141cr. View

13.

Douek D, Brenchley J, Betts M, Ambrozak D, Hill B, Okamoto Y . HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002; 417(6884):95-8. DOI: 10.1038/417095a. View

14.

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View

15.

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View

16.

Calza L, Manfredi R, Colangeli V, DAntuono A, Passarini B, Chiodo F . Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS. 2003; 14(5):356-9. DOI: 10.1258/095646203321605585. View

17.

Noelle R, Roy M, Shepherd D, Stamenkovic I, Ledbetter J, Aruffo A . A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 1992; 89(14):6550-4. PMC: 49539. DOI: 10.1073/pnas.89.14.6550. View

18.

Keler T, Halk E, Vitale L, ONeill T, Blanset D, Lee S . Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol. 2003; 171(11):6251-9. DOI: 10.4049/jimmunol.171.11.6251. View

19.

Palacios R, Santos J . Human immunodeficiency virus infection and systemic lupus erythematosus. Int J STD AIDS. 2004; 15(4):277-8. DOI: 10.1258/095646204773557857. View

20.

Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y . Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. 2004; 104(10):3249-56. DOI: 10.1182/blood-2004-01-0365. View